

**PB 29 of 2023**

**National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2)**

I, Nikolai Tsyganov, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following Determination.

Dated 30 March 2023

**NIKOLAI TSYGANOV**

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

Contents

1 Name 1

2 Commencement 1

3 Authority 1

4 Schedules 1

Schedule 1—Amendments 2

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022) 2

1 Name

 This instrument is the *National Health (Price and Special Patient Contribution) Amendment Determination 2023 (No. 2)*.

 This instrument may also be cited as PB 29 of 2023.

2 Commencement

 (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

| Commencement information |
| --- |
| Column 1 | Column 2 | Column 3 |
| Provisions | Commencement | Date/Details |
| 1. The whole of this instrument | 1 April 2023 |  |

Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

 (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

 This instrument is made under section 85B of the *National Health Act 1953.*

4 Schedules

 Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Price and Special Patient Contribution) Determination 2022 (PB 98 of 2022)

1. Schedule 1- entry for Betamethasone

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Betamethasone | Cream 200 micrograms (as valerate) per g, 100 g | Application | Betnovate 1/5 | 1 | 7.20 | 9.98 |
|  |  |  | Celestone‑M | 1 | 7.20 | 9.52 |
|  | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | 1 | 5.43 | 7.71 |
|  | Cream 500 micrograms (as valerate) per g, 15 g | Application | Betnovate 1/2 | 1 | 2.50 | 4.88 |
|  | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | 1 | 5.43 | 7.71 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Betamethasone | Cream 200 micrograms (as valerate) per g, 100 g | Application | Betnovate 1/5 | 1 | 4.93 | 6.84 |
|  |  |  | Celestone‑M | 1 | 4.93 | 6.52 |
|  | Cream 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | 1 | 3.65 | 5.18 |
|  | Cream 500 micrograms (as valerate) per g, 15 g | Application | Betnovate 1/2 | 1 | 2.50 | 4.88 |
|  | Ointment 500 micrograms (as dipropionate) per g, 15 g | Application | Diprosone | 1 | 3.65 | 5.18 |

1. Schedule 1- entry for Brimonidine

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Brimonidine | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Alphagan | 1 | 11.10 | 12.42 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Brimonidine | Eye drops containing brimonidine tartrate 2 mg per mL, 5 mL | Application to the eye | Alphagan |  1 |  7.60 |  8.51 |

1. Schedule 1- entry for Brinzolamide

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | Azopt | 1 | 13.23 | 17.67 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Brinzolamide | Eye drops 10 mg per mL, 5 mL | Application to the eye | Azopt |  1 |  9.06 |  12.10 |

1. Schedule 1- entry for Carbamazepine

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Carbamazepine | Tablet 100 mg | Oral | Tegretol 100 | 100 | 5.47 | 6.86 |
|  | Tablet 200 mg | Oral | Tegretol 200 | 100 | 9.13 | 10.51 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Carbamazepine | Tablet 100 mg | Oral | Tegretol 100 | 100 | 4.85 | 6.08 |
|  | Tablet 200 mg | Oral | Tegretol 200 | 100 | 8.10 | 9.32 |

1. Schedule 1- entry for Carmellose

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Cellufresh | 1 | 5.45 | 7.38 |
|  | Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Celluvisc | 1 | 5.45 | 7.38 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Carmellose | Eye drops containing carmellose sodium 5 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Cellufresh | 1 | 4.24 | 5.74 |
|  | Eye drops containing carmellose sodium 10 mg per mL, single dose units 0.4 mL, 30 | Application to the eye | Celluvisc | 1 | 4.24 | 5.74 |

1. Schedule 1- entry for Cyproterone

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Androcur | 50 |  | 34.36 |
|  | Tablet containing cyproterone acetate 100 mg | Oral | Androcur‑100 | 50 | 51.88 | 53.19 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Cyproterone | Tablet containing cyproterone acetate 50 mg | Oral | Androcur | 50 | 11.42 | 29.46 |
|  | Tablet containing cyproterone acetate 100 mg | Oral | Androcur‑100 | 50 | 44.47 | 45.59 |

1. Schedule 1- entry for Eprosartan

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Eprosartan | Tablet 400 mg (as mesilate) | Oral | Teveten | 28 | 5.75 | 9.00 |
|  | Tablet 600 mg (as mesilate) | Oral | Teveten | 28 | 14.41 | 17.66 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Eprosartan | Tablet 400 mg (as mesilate) | Oral | Teveten | 28 | 4.32 |  6.77 |
|  | Tablet 600 mg (as mesilate) | Oral | Teveten | 28 | 10.84 |  13.28 |

1. Schedule 1- entry for Fluticasone propionate

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 15.65 | 18.44 |
|   | Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 28.80 | 31.59 |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide Junior | 1 | 6.89 | 10.61 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by Mouth | Flixotide Junior Accuhaler | 1 | 6.89 | 10.61 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by Mouth | Flixotide Accuhaler | 1 | 15.65 | 19.37 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Fluticasone propionate | Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 12.39 | 14.60 |
|   | Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide | 1 | 22.8 | 25.01 |
|  | Pressurised inhalation containing fluticasone propionate 50 micrograms per dose, 120 doses (CFC‑free formulation) | Inhalation by Mouth | Flixotide Junior | 1 | 6.89 | 10.61 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 100 micrograms per dose, 60 doses | Inhalation by Mouth | Flixotide Junior Accuhaler | 1 | 5.45 | 8.40 |
|  | Powder for oral inhalation in breath actuated device containing fluticasone propionate 250 micrograms per dose, 60 doses | Inhalation by Mouth | Flixotide Accuhaler | 1 | 12.39 | 15.34 |

1. Schedule 1- entry for Gliclazide

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Gliclazide | Tablet 60 mg (modified release) | Oral | Diamicron 60mg MR | 60 | 6.73 | 13.82 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Gliclazide | Tablet 60 mg (modified release) | Oral | Diamicron 60mg MR | 60 | 4.48 | 9.19 |

1. Schedule 1- entry for Ketoprofen

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ketoprofen | Capsule 200 mg (sustained release) | Oral | Orudis SR 200 | 28 | 10.26 | 12.04 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ketoprofen | Capsule 200 mg (sustained release) | Oral | Orudis SR 200 | 28 | 7.03 | 8.25 |

1. Schedule 1- entry for Lansoprazole

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zoton FasTabs | 28 | 3.42 | 7.89 |
|  | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | 28 | 5.24 | 9.71 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Lansoprazole | Tablet 15 mg (orally disintegrating) | Oral | Zoton FasTabs | 28 | 3.42 | 7.89 |
|  | Tablet 30 mg (orally disintegrating) | Oral | Zoton FasTabs | 28 | 4.48 | 8.30 |

1. Schedule 1- entry for Levothyroxine

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 10.28 | 11.62 |
|  | Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 10.67 | 12.05 |
|  | Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 10.65 | 11.99 |
|  | Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 12.49 | 13.83 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Levothyroxine | Tablet containing 50 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 9.39 | 10.61 |
|  | Tablet containing 75 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 9.55 | 10.78 |
|  | Tablet containing 100 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 9.73 | 10.95 |
|  | Tablet containing 200 micrograms anhydrous levothyroxine sodium | Oral | Oroxine | 200 | 11.41 | 12.63 |

1. Schedule 1- entry for Medroxyprogesterone

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Medroxyprogesterone | Injection containing medroxyprogesterone acetate 150 mg in 1 mL | Injection | Depo‑Provera | 1 | 13.14 | 19.65 |
|  | Tablet containing medroxyprogesterone acetate 5 mg | Oral | Provera | 56 | 7.44 | 13.67 |
|  | Tablet containing medroxyprogesterone acetate 10 mg | Oral | Provera | 30 | 6.39 | 12.62 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Medroxyprogesterone | Injection containing medroxyprogesterone acetate 150 mg in 1 mL | Injection | Depo‑Provera | 1 | 13.14 | 19.65 |
|  | Tablet containing medroxyprogesterone acetate 5 mg | Oral | Provera | 56 | 5.10 | 9.36 |
|  | Tablet containing medroxyprogesterone acetate 10 mg | Oral | Provera | 30 | 6.39 | 12.62 |

1. Schedule 1- entry for Mercaptopurine

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Mercaptopurine | Tablet containing mercaptopurine monohydrate 50 mg | Oral | Purinethol | 25 | 40.15 | 42.01 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Mercaptopurine | Tablet containing mercaptopurine monohydrate 50 mg | Oral | Purinethol | 25 | 35.60 | 37.25 |

1. Schedule 1- entry for Naproxen

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Naproxen | Tablet 1 g (sustained release) | Oral | Naprosyn SR1000 | 28 | 6.10 | 7.14 |
|  | Tablet 750 mg (sustained release) | Oral | Naprosyn SR750 | 28 | 4.58 | 5.56 |
|  | Tablet containing naproxen sodium 550 mg | Oral | Anaprox 550 | 50 | 5.13 | 6.89 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Naproxen | Tablet 1 g (sustained release) | Oral | Naprosyn SR1000 | 28 | 5.41 | 6.33 |
|  | Tablet 750 mg (sustained release) | Oral | Naprosyn SR750 | 28 | 4.06 | 4.93 |
|  | Tablet containing naproxen sodium 550 mg | Oral | Anaprox 550 | 50 | 4.55 | 6.11 |

1. Schedule 1- entry for Naratriptan

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Naratriptan | Tablet 2.5 mg (as hydrochloride) | Oral | Naramig | 2 | 6.40 | 7.31 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Naratriptan | Tablet 2.5 mg (as hydrochloride) | Oral | Naramig |  2 |  4.98 |  5.69 |

1. Schedule 1- entry for Norethisterone with ethinylestradiol

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Norethisterone with ethinylestradiol | Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral | Brevinor‑1 | 4 | 8.12 | 17.22 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Norethisterone with ethinylestradiol | Pack containing 21 tablets 1 mg‑35 micrograms and 7 inert tablets | Oral | Brevinor‑1 |  4 | 5.56 |  11.80 |

1. Schedule 1- entry for Omeprazole

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | 30 | 4.12 | 10.97 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Omeprazole | Tablet 20 mg (as magnesium) | Oral | Losec Tablets | 30 | 4.00 | 10.65 |

1. Schedule 1- entry for Paraffin

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Refresh Night Time | 1 | 11.47 | 13.18 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Paraffin | Pack containing 2 tubes eye ointment, compound, containing white soft paraffin with liquid paraffin, 3.5 g | Application to the eye | Refresh Night Time | 1 | 7.86 | 9.03 |

1. Schedule 1- entry for Prednisolone

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | Oral | Redipred | 1 | 6.70 | 8.88 |
|  | Tablet 1 mg | Oral | Panafcortelone | 100 | 2.88 | 3.81 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Prednisolone | Oral solution 5 mg (as sodium phosphate) per mL, 30 mL | Oral | Redipred | 1 | 5.94 | 7.87 |
|  | Tablet 1 mg | Oral | Panafcortelone | 100 | 2.88 | 3.81 |

1. Schedule 1- entry for Raloxifene

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | Evista | 28 | 19.12 | 23.77 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Raloxifene | Tablet containing raloxifene hydrochloride 60 mg | Oral | Evista | 28 | 15.66 | 19.47 |

1. Schedule 1- entry for Rasagiline

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Rasagiline | Tablet 1 mg (as mesilate) | Oral | Azilect | 30 | 46.18 | 49.51 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Rasagiline | Tablet 1 mg (as mesilate) | Oral | Azilect | 30 | 39.62 | 42.47 |

1. Schedule 1- entry for Salbutamol

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 2.98 | 4.54 |
|  | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 3.11 | 4.66 |
|  | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by mouth | Asmol CFC‑Free with dose counter | 1 | 4.92 | 6.82 |
|  | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by mouth | Ventolin CFC‑Free with dose counter | 1 | 4.92 | 7.25 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Salbutamol | Nebuliser solution 2.5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 2.98 | 4.54 |
|  | Nebuliser solution 5 mg (as sulfate) in 2.5 mL single dose units, 20 | Inhalation | Ventolin Nebules | 1 | 3.11 | 4.66 |
|  | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by mouth | Asmol CFC‑Free with dose counter | 1 | 4.92 | 5.85 |
|  | Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation) | Inhalation by mouth | Ventolin CFC‑Free with dose counter | 1 | 4.92 | 7.25 |

1. Schedule 1- entry for Verapamil

Omit

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Verapamil | Tablet containing verapamil hydrochloride 80 mg | Oral | Isoptin | 100 | 6.95 | 10.20 |
|  | Tablet containing verapamil hydrochloride 180 mg (sustained release) | Oral | Isoptin 180 SR | 30 | 5.61 | 8.86 |
|  | Tablet containing verapamil hydrochloride 240 mg (sustained release) | Oral | Isoptin SR | 30 | 7.48 | 10.73 |

Insert

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Verapamil | Tablet containing verapamil hydrochloride 80 mg | Oral | Isoptin | 100 | 6.16 | 9.04 |
|  | Tablet containing verapamil hydrochloride 180 mg (sustained release) | Oral | Isoptin 180 SR | 30 | 4.97 | 7.86 |
|  | Tablet containing verapamil hydrochloride 240 mg (sustained release) | Oral | Isoptin SR | 30 | 6.63 | 9.51 |